PL369295A1 - Kompozycja użyteczna w leczeniu stanów patologicznych wrażliwych na aktywację receptora PPAR-gamma - Google Patents

Kompozycja użyteczna w leczeniu stanów patologicznych wrażliwych na aktywację receptora PPAR-gamma

Info

Publication number: PL369295A1
Authority: PL; Poland
Prior art keywords: activation; treatment; ppar; compositions useful; gamma receptor
Prior art date: 2001-03-16

Application number

PL02369295A

Other languages

English (en)

Inventor

Claudio Pisano

Teresa Riccioni

Original Assignee

Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-16

Filing date

2002-03-01

Publication date

2005-04-18

2002-03-01 Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

2005-04-18 Publication of PL369295A1 publication Critical patent/PL369295A1/pl

Links

230000004913 activation Effects 0.000 title abstract 3
230000007170 pathology Effects 0.000 title abstract 3
239000000203 mixture Substances 0.000 title 1
CZIMFHQXGMXDMO-DGROVODQSA-N (3r)-5-hydroxy-7-methoxy-3-[5-[(2r,5r,7r)-2-methyl-1,6-dioxaspiro[4.5]decan-7-yl]pentyl]-3h-2-benzofuran-1-one Chemical compound C([C@H](O1)CCCCC[C@@H]2C=3C=C(O)C=C(C=3C(=O)O2)OC)CC[C@@]21CC[C@@H](C)O2 CZIMFHQXGMXDMO-DGROVODQSA-N 0.000 abstract 2
102000000536 PPAR gamma Human genes 0.000 abstract 2
108010016731 PPAR gamma Proteins 0.000 abstract 2
CZIMFHQXGMXDMO-UHFFFAOYSA-N Spirolaxine Natural products O1C(=O)C=2C(OC)=CC(O)=CC=2C1CCCCCC(O1)CCCC21CCC(C)O2 CZIMFHQXGMXDMO-UHFFFAOYSA-N 0.000 abstract 2
206010022491 Insulin resistant diabetes Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract 1
230000003211 malignant effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229930002330 retinoic acid Natural products 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL02369295A 2001-03-16 2002-03-01 Kompozycja użyteczna w leczeniu stanów patologicznych wrażliwych na aktywację receptora PPAR-gamma PL369295A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2001RM000136A ITRM20010136A1 (it)	2001-03-16	2001-03-16	Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.

Publications (1)

Publication Number	Publication Date
PL369295A1 true PL369295A1 (pl)	2005-04-18

Family

ID=11455333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02369295A PL369295A1 (pl)	2001-03-16	2002-03-01	Kompozycja użyteczna w leczeniu stanów patologicznych wrażliwych na aktywację receptora PPAR-gamma

Country Status (19)

Country	Link
US (4)	US6897235B2 (pl)
EP (1)	EP1368025B1 (pl)
JP (1)	JP4276842B2 (pl)
KR (1)	KR100851678B1 (pl)
CN (2)	CN1286456C (pl)
AT (1)	ATE308984T1 (pl)
AU (1)	AU2002247951B2 (pl)
BR (1)	BR0208157A (pl)
CA (1)	CA2440979C (pl)
CZ (1)	CZ20032523A3 (pl)
DE (1)	DE60207215T2 (pl)
DK (1)	DK1368025T3 (pl)
ES (1)	ES2249568T3 (pl)
HU (1)	HUP0303518A3 (pl)
IT (1)	ITRM20010136A1 (pl)
MX (1)	MXPA03008317A (pl)
PL (1)	PL369295A1 (pl)
SK (1)	SK12752003A3 (pl)
WO (1)	WO2002074291A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7041691B1 (en)	1999-06-30	2006-05-09	Amgen Inc.	Compounds for the modulation of PPARγ activity
US20030171399A1 (en)	2000-06-28	2003-09-11	Tularik Inc.	Quinolinyl and benzothiazolyl modulators
ES2327639T3 (es) *	2003-05-14	2009-11-02	Dsm Ip Assets B.V.	Uso de derivados de ftalida para el tratamiento y prevecion de diabetes mellitus.
US7223761B2 (en)	2003-10-03	2007-05-29	Amgen Inc.	Salts and polymorphs of a potent antidiabetic compound
KR20090066289A (ko)	2006-09-08	2009-06-23	로드아일랜드하스피틀	알코올 유발성 뇌 질환의 치료, 예방 및 역행

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH07285862A (ja) *	1994-04-21	1995-10-31	Kokka Iyaku Kanrikyoku Shisen Kokinso Kogyo Kenkyusho	脂質低下剤
JPH107557A (ja) *	1996-06-17	1998-01-13	Banyu Pharmaceut Co Ltd	抗腫瘍性物質スピロラキシン
US6440961B1 (en)	1997-10-27	2002-08-27	Dr. Reddy's Research Foundation	Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
IT1317001B1 (it) *	2000-03-13	2003-05-26	Sigma Tau Ind Farmaceuti	Uso della spirolaxina per il trattamento di patologie associate ad unaalterata angiogenesi.

2001
- 2001-03-16 IT IT2001RM000136A patent/ITRM20010136A1/it unknown
2002
- 2002-03-01 HU HU0303518A patent/HUP0303518A3/hu unknown
- 2002-03-01 MX MXPA03008317A patent/MXPA03008317A/es active IP Right Grant
- 2002-03-01 ES ES02717031T patent/ES2249568T3/es not_active Expired - Lifetime
- 2002-03-01 KR KR1020037012030A patent/KR100851678B1/ko not_active Expired - Fee Related
- 2002-03-01 SK SK1275-2003A patent/SK12752003A3/sk unknown
- 2002-03-01 CA CA2440979A patent/CA2440979C/en not_active Expired - Fee Related
- 2002-03-01 DE DE60207215T patent/DE60207215T2/de not_active Expired - Lifetime
- 2002-03-01 JP JP2002572999A patent/JP4276842B2/ja not_active Expired - Fee Related
- 2002-03-01 CN CNB028081382A patent/CN1286456C/zh not_active Expired - Fee Related
- 2002-03-01 CZ CZ20032523A patent/CZ20032523A3/cs unknown
- 2002-03-01 AT AT02717031T patent/ATE308984T1/de not_active IP Right Cessation
- 2002-03-01 PL PL02369295A patent/PL369295A1/pl not_active Application Discontinuation
- 2002-03-01 EP EP02717031A patent/EP1368025B1/en not_active Expired - Lifetime
- 2002-03-01 US US10/471,786 patent/US6897235B2/en not_active Expired - Fee Related
- 2002-03-01 DK DK02717031T patent/DK1368025T3/da active
- 2002-03-01 AU AU2002247951A patent/AU2002247951B2/en not_active Ceased
- 2002-03-01 WO PCT/IT2002/000127 patent/WO2002074291A2/en not_active Ceased
- 2002-03-01 BR BR0208157-1A patent/BR0208157A/pt not_active IP Right Cessation
- 2002-03-01 CN CNB2006100057819A patent/CN100462073C/zh not_active Expired - Fee Related
2004
- 2004-07-13 US US10/889,030 patent/US20040242675A1/en not_active Abandoned
- 2004-07-13 US US10/889,029 patent/US7276533B2/en not_active Expired - Fee Related
- 2004-10-18 US US10/965,740 patent/US20050131060A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE308984T1 (de)	2005-11-15
US20050131060A1 (en)	2005-06-16
US20040241228A1 (en)	2004-12-02
US6897235B2 (en)	2005-05-24
HK1096850A1 (zh)	2007-06-15
HUP0303518A3 (en)	2005-12-28
JP4276842B2 (ja)	2009-06-10
US20040092540A1 (en)	2004-05-13
CA2440979C (en)	2010-07-13
US20040242675A1 (en)	2004-12-02
CN1286456C (zh)	2006-11-29
CZ20032523A3 (cs)	2004-05-12
ITRM20010136A1 (it)	2002-09-16
CN1839823A (zh)	2006-10-04
HK1075006A1 (en)	2005-12-02
JP2004523578A (ja)	2004-08-05
SK12752003A3 (sk)	2004-01-08
MXPA03008317A (es)	2003-12-11
WO2002074291A2 (en)	2002-09-26
HUP0303518A2 (hu)	2004-03-01
DK1368025T3 (da)	2005-12-19
DE60207215D1 (de)	2005-12-15
EP1368025A2 (en)	2003-12-10
CN1610545A (zh)	2005-04-27
ITRM20010136A0 (it)	2001-03-16
AU2002247951B2 (en)	2007-03-01
CA2440979A1 (en)	2002-09-26
KR20040025905A (ko)	2004-03-26
ES2249568T3 (es)	2006-04-01
EP1368025B1 (en)	2005-11-09
BR0208157A (pt)	2004-03-02
WO2002074291A3 (en)	2003-03-13
DE60207215T2 (de)	2006-07-20
KR100851678B1 (ko)	2008-08-13
CN100462073C (zh)	2009-02-18
US7276533B2 (en)	2007-10-02

Legal Events

Date	Code	Title	Description
2012-05-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
BR0214343A (pt)	2004-09-14	Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
MY134568A (en)	2007-12-31	Cb2 receptor agonists
GEP20074197B (en)	2007-09-10	5ht2c receptor modulators
MXPA05008760A (es)	2006-03-21	Derivados de acido aminofosfonico, sales del mismo y moduladores del receptor sip.
SE0201544D0 (sv)	2002-05-17	Novel compounds and thier use
ATE303149T1 (de)	2005-09-15	Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
MXPA04000210A (es)	2004-07-23	Conjugados quelantes mejorados.
ES2421948T3 (es)	2013-09-06	Compuestos y composiciones para suministrar agentes activos
ZA200604114B (en)	2007-08-29	Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
MY133507A (en)	2007-11-30	New peroxy-carboxylic acid and aqueous compositions thereof
ATE368023T1 (de)	2007-08-15	Hydroxydiphenyletherverbindungen
ES2187261A1 (es)	2003-05-16	Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
MXPA05006889A (es)	2006-04-07	Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
SE9804212D0 (sv)	1998-12-04	Compounds
SE9801494D0 (sv)	1998-04-28	Novel use
MXPA03008317A (es)	2003-12-11	Composiciones utiles para el tratamiento de patologias que responden a la activavion del receptor ppar-gama.
DE60201074D1 (en)	2004-09-30	Pyrazolopyridinderivate
PL1831239T3 (pl)	2010-08-31	Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu
TR200001121T2 (tr)	2000-09-21	Antiromatizmal madde.
SE9904128D0 (sv)	1999-11-15	Novel compounds
DK0745081T3 (da)	2002-05-21	Indan-2-mercaptoacetylamiddisulfidderivater, der er anvendelige som enkephalinase-inhibitorer
BR0007183A (pt)	2002-02-05	Isonipectoamidas para o tratamento de distúrbios mediados por integrina
BR0311590A (pt)	2005-05-10	Agonistas de brs-3 não-peptìdicos
TR200100906T2 (tr)	2001-07-23	Trombin inhibitörleri olarak benzamid türevleri
MXPA04000876A (es)	2004-05-21	Derivados de acido butirico.